ImmuPharma plc (LON:IMM – Get Free Report) shares hit a new 52-week low during trading on Wednesday. The stock traded as low as GBX 2.80 and last traded at GBX 2.96, with a volume of 3,759,808 shares traded. The stock had previously closed at GBX 3.13.
ImmuPharma Stock Performance
The stock has a 50-day moving average of GBX 3.57 and a 200 day moving average of GBX 4.58. The firm has a market capitalization of £17.63 million, a P/E ratio of -3.40 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last issued its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. On average, equities analysts predict that ImmuPharma plc will post -339.00 EPS for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
